447 related articles for article (PubMed ID: 17322365)
1. Murine models to evaluate novel and conventional therapeutic strategies for cancer.
Talmadge JE; Singh RK; Fidler IJ; Raz A
Am J Pathol; 2007 Mar; 170(3):793-804. PubMed ID: 17322365
[TBL] [Abstract][Full Text] [Related]
2. Models of metastasis in drug discovery.
Talmadge JE
Methods Mol Biol; 2010; 602():215-33. PubMed ID: 20012401
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics.
Newell DR; Burtles SS; Fox BW; Jodrell DI; Connors TA
Br J Cancer; 1999 Nov; 81(5):760-8. PubMed ID: 10555743
[TBL] [Abstract][Full Text] [Related]
4. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved.
Kerbel RS
Cancer Biol Ther; 2003; 2(4 Suppl 1):S134-9. PubMed ID: 14508091
[TBL] [Abstract][Full Text] [Related]
5. What is the optimal rodent model for anti-tumor drug testing?
Kerbel RS
Cancer Metastasis Rev; 1998-1999; 17(3):301-4. PubMed ID: 10352884
[TBL] [Abstract][Full Text] [Related]
6. The use of animal models in cancer drug discovery and development.
Curt GA
Stem Cells; 1994 Jan; 12(1):23-9. PubMed ID: 8142918
[TBL] [Abstract][Full Text] [Related]
7. [Preclinical evaluation of anticancer drugs: a model remaining a model!].
Lavelle F
Bull Cancer; 1998 Oct; 85(10):837-42. PubMed ID: 9835860
[TBL] [Abstract][Full Text] [Related]
8. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
9. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
Frijhoff AF; Conti CJ; Senderowicz AM
Mol Carcinog; 2004 Apr; 39(4):183-94. PubMed ID: 15057870
[TBL] [Abstract][Full Text] [Related]
10. Orthotopic models are necessary to predict therapy of transplantable tumors in mice.
Killion JJ; Radinsky R; Fidler IJ
Cancer Metastasis Rev; 1998-1999; 17(3):279-84. PubMed ID: 10352881
[TBL] [Abstract][Full Text] [Related]
11. N-ω-chloroacetyl-L-ornithine has in-vitro activity against cancer cell lines and in-vivo activity against ascitic and solid tumors.
Vargas-Ramírez AL; Medina-Enríquez MM; Cordero-Rodríguez NI; Ruiz-Cuello T; Aguilar-Faisal L; Trujillo-Ferrara JG; Alcántara-Farfán V; Rodríguez-Páez L
Anticancer Drugs; 2016 Jul; 27(6):508-18. PubMed ID: 26918391
[TBL] [Abstract][Full Text] [Related]
12. Genetically engineered models have advantages over xenografts for preclinical studies.
Becher OJ; Holland EC
Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
[TBL] [Abstract][Full Text] [Related]
13. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
Kerbel RS
Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
[TBL] [Abstract][Full Text] [Related]
14. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
15. Current status of cancer drug development: failure or limited success?
Grindey GB
Cancer Cells; 1990 Jun; 2(6):163-71. PubMed ID: 2201343
[TBL] [Abstract][Full Text] [Related]
16. Quantification of human Alu sequences by real-time PCR--an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants.
Schneider T; Osl F; Friess T; Stockinger H; Scheuer WV
Clin Exp Metastasis; 2002; 19(7):571-82. PubMed ID: 12498386
[TBL] [Abstract][Full Text] [Related]
17. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
18. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
19. Human cancer xenografts in immunocompromised mice provide an advanced genuine tumor model for research and drug development-A revisit of murine models for human cancers.
Yang QE
Biochim Biophys Acta Gen Subj; 2021 Aug; 1865(8):129929. PubMed ID: 33991617
[TBL] [Abstract][Full Text] [Related]
20. In vivo models of childhood leukemia for preclinical drug testing.
Bachmann PS; Lock RB
Curr Drug Targets; 2007 Jun; 8(6):773-83. PubMed ID: 17584033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
